골다공증의 진단과 치료
The Diagnosis and Treatment of Osteoporosis
0
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
골다공증은 골밀도와 골의 질로 구성되는골의 강도가 손상됨으로 골절의 위험이 높아지는 골격질환이며, 최근 유병율이 점차 증가하고 있는 추세이다. 임상적으로 무증상인 경우가 많으며 방사선학적 검사인 단순 방사선 검사, 골 스캔, CT, MRI 등이 골밀도 및 골절의진단에 유용하다. 골밀도의 정량적 검사로는이중에너지 방사선 흡수법, 정량적 전산화 단층촬영이 사용되고 있다. 골다공증의 진단은WHO 기준에 따라 T-score가 -2.5 이하일 경우 진단할 수 있다. 그 외에 생화학적 골표지자들도 진단에 도움이 된다. 골다공증 치료제는 골흡수억제제와 골형성자극제(formation stimulator)로 나눌 수 있는데 골흡수억제제로는 칼슘, 에스트로겐, 칼시토닌, 비스포스포네이트(bisphosphonate), 비타민 D 등이 있으며골량을 증가시키는 골형성자극제로는 현재 부갑상선 호르몬이 유일하며 최근 strontium ranelate가 추가되었다. 일일 1200 mg의 칼슘과 800 IU 의 비타민 D 섭취가 권장되고 있으며, 폐경기 여성에서 에스트로겐이 효과가 입증되었고 골다공증으로 인한 통증에는 칼시토닌이 효과가 있다. 비스포스포네이트는 폐경후 골다공증의 치료, 예방 및 스테로이드에 의한 골다공증 치료에 대해 FDA의 승인을 받았다. 폐경 후 골다공증의 치료, 예방에 사용되는SERM은 골의 질을 향상시킴으로써 골절을 예방한다고 알려져 있다. 골형성자극제인 부갑상선 호르몬이 골절의 위험을 감소시킨다고 보고된 바 있으며, strontium은 최근에 개발된 약제로 3상 연구에서 골절 위험율 감소효과를 보였으나 더 많은 연구가 필요할 것으로 생각된다.
Abstract
Osteoporosis, a disease characterized by low bone mass and microarchitectural deterioration of bone tissue leading to enhanced bone fragility and fracture risk, is a major public health problem. The diagnostic methods for osteoporosis include simple radiography, bone scan, DXA (Dual energy X-ray Absortiometry) and biochemical markers of bone turnover. Optimal treatment and prevention of osteoporosis require modification of risk factors, particularly smoking cessation, adequate physical activity, and attention to diet, in addition to pharmacologic intervention. The estrogens and raloxifene both prevent bone loss in postmenopausal women, and the estrogens probably also decrease the risk of first fracture. There is good evidence that raloxifene prevents further fractures in postmenopausal women who already have had fractures and some evidence that estrogen does as well. Bisphosphonate prevents bone loss and reduces fractures in healthy and osteoporotic postmenopausal women and in osteoporotic men as well. Risedronate is more potent and has fewer side effects than alendronate and reduces the incidence of fractures in osteoporotic women. Calcitonin increases bone mineral density in early postmenopausal women and men with idiopathic osteoporosis, and also reduces the risk of new fractures in osteoporotic women. All of the agents discussed above prevent bone resorption, whereas teriparatide and strontium increase bone formation and are effective in the treatment of osteoporotic women and men. New avenues for targeting osteoporosis will emerge as our knowledge of the regulatory mechanisms of bone remodeling increases, although issues of tissue specificity may remain to be addressed.
참고문헌 (24)
- NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, "Osteoporosis Prevention, Diagnosis, and Therapy", JAMA, 285, pp.785~795 (2001)
- Mayo-Smith W, "Radiographic appearance of osteopenia", Radiol Clin North Am, 29(1), pp.37~47 (1991)
- Blake GM, "Bone densitometry and the diagnosis of osteoporosis", Semin Nucl Med, pp.69~81 (2001)
- Patel R, "Long-term precision of DXA scanning assessed over seven years in forty postmenopausal women", Osteoporos Int, 11(1), pp.68~75 (2000)
- The Korean Society of Bone Metabolism, "Osteoporosis", pp.113~181 (2006), Hanmi-Euihak
- Recker RR, "Correcting calcium nutritional deficiency prevents spine fractures in elderly women", J Bone Miner Res, 11(12), pp.1961~1966 (1996)
- "Am J Med", 1995, 331~335
- Nieves JW, "Calcium potentiates the effect of estrogen and calcitonin on bone mass: review and analysis", Am J Clin Nutr, 67(1), pp.118~24 (1998)
- Tang BM, "Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis", Lancet, 370, pp.657~666 (2007)
- Kimble RB, "The functional block of TNF but not of IL-6 prevents bone loss in ovariectomized mice", J Bone Miner Res, 12(6), pp.935~941 (1997)
- Gallagher JC, "Effect of estrogen on calcium absorption and serum vitamin D metabolites in postmenopausal osteoporosis", J Clin Endocrinol Metab, 51(6), pp.1359~1364 (1980)
- The Writing Group for the PEPI Trial, "Effects of estrogen or estrogen", progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen, JAMA, pp.1995, 273(3)[DOI]
- Cauley JA, "Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial", JAMA, 290(13), pp.1729~1738 (2003)
- Chesnut CH 3rd, "A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group", Am J Med, 109(4), pp.267~276 (2000)
- Watts NB, "Intermittent cyclical etidronate treatment of postmenopausal osteoporosis", N Engl J Med, 323(2), pp.73~79 (1990)
- Liberman UA, "Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group", N Engl J Med, 33(22), pp.1437~1443 (1995)
- Harris ST, "Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group", JAMA, 282(14), pp.1344~1352 (1999)
- Chesnut III CH, "Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis", J Bone Miner Res, 19(8), pp.1241~1249 (2004)
- Reid IR, "Intravenous zoledronic acid in postmenopausal women with low bone mineral density", N Engl J Med, 346(9), pp.653~661 (2002)
- Sook-Bin Woo, "Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws", Ann Intern Med, 144, pp.753~761 (2006)
- Canalis E, "Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures", J Clin Invest, 83(1), pp.60~65 (1989)
- Neer RM, "Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis", N Engl J Med, 344(19), pp.1434~1441 (2001)
- Marie PJ, "Optimizing bone metabolism in osteoporosis: insight into the pharmacologic profile of strontium ranelate", Osteoporos Int, 14(Suppl 3), pp.S9~S12 (2003)
- Meunier PJ, "The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis", N Engl J Med, 350(5), pp.459~468 (2004)